Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives $74.38 Consensus Target Price from Analysts

Apellis Pharmaceuticals, Inc. (NASDAQ:APLSGet Free Report) has been given a consensus recommendation of “Moderate Buy” by the sixteen ratings firms that are presently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $74.38.

Several equities research analysts recently commented on APLS shares. Wedbush cut their target price on shares of Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Wells Fargo & Company lowered their price target on shares of Apellis Pharmaceuticals from $57.00 to $48.00 and set an “equal weight” rating for the company in a report on Thursday, May 23rd. JPMorgan Chase & Co. raised their price target on shares of Apellis Pharmaceuticals from $78.00 to $79.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. Piper Sandler started coverage on shares of Apellis Pharmaceuticals in a report on Friday, May 31st. They set a “neutral” rating and a $46.00 price target for the company. Finally, Citigroup lowered their price target on shares of Apellis Pharmaceuticals from $67.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, May 8th.

Read Our Latest Stock Analysis on Apellis Pharmaceuticals

Insider Activity at Apellis Pharmaceuticals

In related news, CFO Timothy Eugene Sullivan sold 4,000 shares of Apellis Pharmaceuticals stock in a transaction on Monday, April 1st. The shares were sold at an average price of $58.66, for a total value of $234,640.00. Following the completion of the sale, the chief financial officer now owns 93,338 shares of the company’s stock, valued at approximately $5,475,207.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, insider Nur Nicholson sold 11,220 shares of the business’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $57.56, for a total value of $645,823.20. Following the transaction, the insider now directly owns 56,287 shares of the company’s stock, valued at approximately $3,239,879.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Timothy Eugene Sullivan sold 4,000 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $58.66, for a total transaction of $234,640.00. Following the completion of the transaction, the chief financial officer now directly owns 93,338 shares in the company, valued at $5,475,207.08. The disclosure for this sale can be found here. In the last 90 days, insiders sold 192,012 shares of company stock valued at $9,608,319. 6.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Future Financial Wealth Managment LLC purchased a new position in shares of Apellis Pharmaceuticals in the 1st quarter worth about $29,000. Covestor Ltd boosted its holdings in shares of Apellis Pharmaceuticals by 564.2% in the 3rd quarter. Covestor Ltd now owns 797 shares of the company’s stock worth $30,000 after buying an additional 677 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Apellis Pharmaceuticals in the 1st quarter worth about $89,000. CWA Asset Management Group LLC bought a new stake in Apellis Pharmaceuticals in the 4th quarter valued at about $205,000. Finally, Woodward Diversified Capital LLC bought a new stake in Apellis Pharmaceuticals in the 4th quarter valued at about $210,000. 96.29% of the stock is owned by hedge funds and other institutional investors.

Apellis Pharmaceuticals Trading Down 1.1 %

Shares of Apellis Pharmaceuticals stock opened at $41.05 on Tuesday. The company has a market capitalization of $4.98 billion, a price-to-earnings ratio of -11.86 and a beta of 0.95. The company has a quick ratio of 3.02, a current ratio of 3.77 and a debt-to-equity ratio of 0.35. Apellis Pharmaceuticals has a 12-month low of $19.83 and a 12-month high of $94.75. The firm’s 50-day moving average price is $46.87 and its two-hundred day moving average price is $56.44.

Apellis Pharmaceuticals (NASDAQ:APLSGet Free Report) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.54) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.54). Apellis Pharmaceuticals had a negative net margin of 79.67% and a negative return on equity of 160.77%. The company had revenue of $172.33 million for the quarter, compared to the consensus estimate of $163.37 million. During the same period last year, the company posted ($1.56) EPS. The firm’s quarterly revenue was up 284.3% compared to the same quarter last year. On average, analysts forecast that Apellis Pharmaceuticals will post -1.15 earnings per share for the current fiscal year.

Apellis Pharmaceuticals Company Profile

(Get Free Report

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

Read More

Analyst Recommendations for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.